{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:17:49Z","timestamp":1746591469251,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40264-019-00853-y","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T13:02:36Z","timestamp":1564578156000},"page":"1365-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-9562","authenticated-orcid":false,"given":"Rachel E.","family":"Sobel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Fram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-3653","authenticated-orcid":false,"given":"Andrew","family":"Bate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"853_CR1","volume-title":"Pharmacoepidemiology","year":"2006","unstructured":"Strom BL, editor. Pharmacoepidemiology. 4th ed. West Sussex: Wiley; 2006.","edition":"4"},{"key":"853_CR2","unstructured":"US Food and Drug Administration Draft Guidance. REMS assessment: planning and reporting guidance for industry. 2019. \n                    https:\/\/www.fda.gov\/media\/119790\/download\n                    \n                  . Accessed 8 May 2019."},{"key":"853_CR3","unstructured":"US Food and Drug Administration Draft Guidance. Survey methodologies to assess REMS goals that relate to knowledge guidance for industry. 2019. \n                    https:\/\/www.fda.gov\/media\/119789\/download\n                    \n                  . Accessed 8 May 2019."},{"key":"853_CR4","unstructured":"EU GVP Module V. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2016\/02\/WC500202424.pdf\n                    \n                  . Accessed 25 Mar 2019."},{"key":"853_CR5","unstructured":"EU GVP Module XVI, Revision 2. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/02\/WC500162051.pdf\n                    \n                  . Accessed 25 Mar 2019."},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-013-0126-7","volume":"37","author":"AK Banerjee","year":"2014","unstructured":"Banerjee AK, Zomerdijk IM, Wooder S, et al. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014;37:33. \n                    https:\/\/doi.org\/10.1007\/s40264-013-0126-7\n                    \n                  .","journal-title":"Drug Saf"},{"key":"853_CR7","unstructured":"Levinson DR. FDA lacks comprehensive data to determine whether REMS improve drug safety. Institute of Medicine, Office of the US Inspector General. \n                    https:\/\/oig.hhs.gov\/oei\/reports\/oei-04-11-00510.pdf\n                    \n                  . Accessed 25 Mar 2019."},{"key":"853_CR8","first-page":"219","volume":"24-S1","author":"C de Luise","year":"2015","unstructured":"de Luise C, Schade R, Trifiro G, Pederson L, Herings R, Sturkenboom M. Trends in prescribing patterns for cabergoline in 4 European countries. Pharmacoepidemiol Drug Saf. 2015;24-S1:219.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.320","volume":"99","author":"R Ball","year":"2016","unstructured":"Ball R, Robb M, Anderson S, Dal Pan G. The FDA\u2019s sentinel initiative\u2014a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99:265\u20138. \n                    https:\/\/doi.org\/10.1002\/cpt.320\n                    \n                  .","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"853_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaci.2015.09.057","volume":"137","author":"Butler","year":"2016","unstructured":"Butler, et al. Changing patterns of asthma medication use related to US Food and Drug Administration long-acting \u03b22-agonist regulation from 2005\u20132011. J Allergy Clin Immunol. 2016;137(3):710\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pds.4392","volume":"27","author":"RE Sobel","year":"2018","unstructured":"Sobel RE, Bate A, Marshall J, et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System\u2019s analytic tools. Pharmacoepidemiol Drug Saf. 2018;27:332\u20139. \n                    https:\/\/doi.org\/10.1002\/pds.4392\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/pds.4434","volume":"27","author":"P Vora","year":"2018","unstructured":"Vora P, Artime E, Soriano-Gabarr\u00f3 M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies. Pharmacoepidemiol Drug Saf. 2018;27:695\u2013706. \n                    https:\/\/doi.org\/10.1002\/pds.4434\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"853_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10618-009-0152-3","volume":"20","author":"GN Nor\u00e9n","year":"2010","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361\u201387.","journal-title":"Data Min Knowl Discov"},{"issue":"1","key":"853_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40264-014-0251-y","volume":"38","author":"S Cederholm","year":"2015","unstructured":"Cederholm S, Hill G, Asiimwe A, Bate A, Bhayat F, Brobert GP, Bergvall T, Ansell D, Star K, Nor\u00e9n GN. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network. Drug Saf. 2015;38(1):87\u2013100.","journal-title":"Drug Saf"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40264-018-0675-x","volume":"41","author":"K Donegan","year":"2018","unstructured":"Donegan K, Owen R, Bird H, Burch B, Smith A, Tregunno P. Exploring the potential routine use of electronic healthcare record data to strengthen early signal assessment in UK medicines regulation: proof-of-concept study. Drug Saf. 2018;41:899\u2013910.","journal-title":"Drug Saf"},{"issue":"6","key":"853_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"853_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Sa. 2016;39(6):469\u201390.","journal-title":"Drug Sa"},{"issue":"S1","key":"853_CR19","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1007\/s40264-013-0095-x","volume":"36","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Bergvall T, Ryan PB, et al. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(S1):S107\u201321.","journal-title":"Drug Saf"},{"key":"853_CR20","unstructured":"UK MHRA Safety Communication on Potential Increased Risk of Fractures with PPIs. \n                    https:\/\/www.gov.uk\/drug-safety-update\/proton-pump-inhibitors-in-long-term-use-increased-risk-of-fracture#further-information\n                    \n                  . Accessed 25 Mar 2019."},{"issue":"4","key":"853_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14236\/jhi.v19i4.820","volume":"19","author":"B Blak","year":"2011","unstructured":"Blak B, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. J Innov Health Inform. 2011;19(4):251\u20135. \n                    https:\/\/doi.org\/10.14236\/jhi.v19i4.820\n                    \n                  .","journal-title":"J Innov Health Inform"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"Y-X Yu-Xiao Yang","year":"2006","unstructured":"Yu-Xiao Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947\u201353.","journal-title":"JAMA."},{"issue":"8","key":"853_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1592\/phco.28.8.951","volume":"28","author":"JA Kaye","year":"2008","unstructured":"Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951\u20139.","journal-title":"Pharmacotherapy"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","volume":"124","author":"EW Yu","year":"2011","unstructured":"Yu EW, Bauer SC, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519\u201326. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2011.01.007\n                    \n                  .","journal-title":"Am J Med"},{"key":"853_CR25","unstructured":"CVW Analytics. \n                    https:\/\/www.commoninf.com\/products\/commonwealth-vigilance-workbench-cvw\/cvw-analytics\/\n                    \n                  . Accessed 25 Mar 2019."},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/pds.3474","volume":"22","author":"K Juhlin","year":"2013","unstructured":"Juhlin K, Ye X, Star K, Nor\u00e9n GN. Outlier removal to uncover patterns in adverse drug reaction surveillance\u2014a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22:1119\u201329. \n                    https:\/\/doi.org\/10.1002\/pds.3474\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/pds.4043","volume":"25","author":"F Othman","year":"2016","unstructured":"Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf. 2016;25:1079\u201387. \n                    https:\/\/doi.org\/10.1002\/pds.4043\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.4135","volume":"26","author":"SM Wallerstedt","year":"2017","unstructured":"Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection\u2014a cross-sectional population-based study. Pharmacoepidemiol Drug Saf. 2017;26:9\u201316. \n                    https:\/\/doi.org\/10.1002\/pds.4135\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"853_CR29","doi-asserted-by":"publisher","first-page":"e0208461","DOI":"10.1371\/journal.pone.0208461","volume":"13","author":"H Bustillos","year":"2018","unstructured":"Bustillos H, Leer K, Kitten A, Reveles KR. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. PLoS One. 2018;13(11):e0208461. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0208461\n                    \n                  .","journal-title":"PLoS One"},{"key":"853_CR30","unstructured":"UK MHRA\u00a0Public assessment report: pharmacy to general sales list, reclassification nexium control 20mg gastro-resistant tablets (esomeprazole). 2015.\u00a0\n                    http:\/\/www.mhra.gov.uk\/home\/groups\/s-par\/documents\/websiteresources\/con504924.pdf\n                    \n                  . Accessed 25 Mar 2019."},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/pds.4203","volume":"26","author":"ME Nyeland","year":"2017","unstructured":"Nyeland ME, Laursen MV, Callr\u00e9us T. Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data. Pharmacoepidemiol Drug Saf. 2017;26:607\u201314. \n                    https:\/\/doi.org\/10.1002\/pds.4203\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"853_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-015-0291-y","volume":"38","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015;38(6):565\u201375. \n                    https:\/\/doi.org\/10.1007\/s40264-015-0291-y\n                    \n                  .","journal-title":"Drug Saf."},{"issue":"9","key":"853_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/pds.3677","volume":"23","author":"A Ogdie","year":"2014","unstructured":"Ogdie A, Alehashemi S, Love TJ, et al. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf. 2014;23(9):918\u201322. \n                    https:\/\/doi.org\/10.1002\/pds.3677\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/pds.3926","volume":"25","author":"L Cea Soriano","year":"2016","unstructured":"Cea Soriano L, Soriano-Gabarr\u00f3 M, Garc\u00eda Rodr\u00edguez LA. Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use? Pharmacoepidemiol Drug Saf. 2016;25:392\u20138. \n                    https:\/\/doi.org\/10.1002\/pds.3926\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00853-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00853-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00853-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T23:50:08Z","timestamp":1596066608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00853-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00853-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"31 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding was provided to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rachel E. Sobel was an employee and is a shareholder of Pfizer Inc;\u00a0Andrew Bate is an\u00a0employee and shareholder of Pfizer Inc., the manufacturer of one or more PPIs described in this study; the views expressed in this manuscript are their own and do not necessarily reflect those of Pfizer. They contributed to the study design, analysis, and interpretation of data, the writing of the report, and the decision to submit the report for publication. William Blackwell and David M. Fram are employees of Commonwealth Informatics Inc, a Genpact company, which developed the Commonwealth Vigilance Workbench software that was used to generate the chronographs and associated analyses for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was reviewed and approved by the UK Scientific Review Committee (SRC Reference #17THIN012).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}